Watch the HDRS 2017 morning session livestreamed 8:30 AM to 9:55 AM on Fri. Oct13, 2017. You can watch the mid-day session from 10:45 AM to 12:30 PM here and the afternoon session from 1:50 PM to 3:00 PM here. Watch the morning and afternoon sessions of last year's 2016 symposium here.
When & WhereDate: Friday, October 13, 2017
Time: 8:00 a.m. to 3:00 p.m.
Location: Mission Bay Campus
Genentech Hall Building, Byers Auditorium – GH 106
600 16th Street, San Francisco, CA
BackgroundWe welcome research from the diversity of disciplines at UC San Francisco, both quantitative and qualitative work and research studies based outside the United States if these studies address disparities by race and ethnicity or social class.
The goal is to build community among disparities researchers from many disciplines and across units, schools, and campus sites. We would like to gather together all the amazing and outstanding disparities research in order to showcase this fine work and inspire future direction.
Hannah Valantine is the first NIH Chief Officer for Scientific Workforce Diversity, and a Senior Investigator in the Intramural Research Program at the National Heart, Lung, and Blood Institute. Prior to starting this position in April 2014, Dr. Valantine was Professor of Cardiovascular Medicine and the Senior Associate Dean for Diversity and Leadership at Stanford, a leadership position she held since November 2004. She is nationally recognized for her transformative approaches to diversity and is a recipient of the NIH Director’s Pathfinder Award for Diversity in the Scientific Workforce. She is currently leading NIH efforts to promote diversity through innovation across the NIH-funded biomedical workforce through a range of evidence-based approaches. Dr. Valantine maintains an active clinical research program that continues to have high impact on patient care. Current research extends her previous finding that an organ transplant is essentially a genome transplant, and that monitoring the level of donor DNA in a recipient’s blood as a marker of organ damage will detect early stages of rejection. She is currently overseeing a multi-site consortium of mid-Atlantic transplant centers to validate these findings clinically toward the development of a non-invasive tool for detecting early signs of organ rejection.
ProgramFollow along and plan your day with the symposium program.
Further InformationFor additional information, please contact the scientific organizers:
Tung Nguyen (email@example.com) or Victor Fujimoto (firstname.lastname@example.org).